Bacterial Efflux Pump Inhibitors for Antibiotic Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increasing prevalence of antibiotic-resistant bacterial strains due to mechanisms such as efflux pumps threatens the clinical utility of antibacterial therapy, leading to higher morbidity, mortality, and treatment costs in hospitals.
Innovation Solution
Compounds of formula I, which inhibit bacterial efflux pumps when combined with known antibiotics, lower the minimum inhibitory concentration required to inhibit bacterial cell growth, potentially by inhibiting efflux pumps.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If efflux pumps are active in bacteria, then bacteria can expel antibiotics and survive, but the concentration of antibiotic at the target site decreases
Solution Approach 1:
The patent introduces efflux pump inhibitors as intermediary substances that block the efflux pump mechanism. These inhibitors act as mediators between the antibiotic and the bacterial efflux pump, preventing the pump from expelling the antibiotic while allowing the antibiotic to reach its target site and exert its therapeutic effect.
2Reliability
If antibiotics are used to treat bacterial infections, then bacterial growth is inhibited, but antibiotic resistance develops through efflux mechanisms
Solution Approach 1:
The patent applies preliminary anti-action by using efflux pump inhibitors to preemptively block the resistance mechanism before the antibiotic encounters it. The inhibitors are administered alongside or before the antibiotic to prevent the efflux pump from developing or executing its resistance function, thereby countering resistance before it can compromise treatment efficacy.
3Reliability
If efflux pumps increase drug efflux from cells, then bacterial survival is enhanced, but treatment costs and hospitalization duration increase
Solution Approach 1:
The efflux pump inhibitor serves as an intermediary that restores the effectiveness of standard antibiotics by blocking the efflux mechanism. This combination approach allows for shorter treatment durations and reduced hospitalization by overcoming resistance without requiring prolonged antibiotic exposure or more expensive alternative treatments.
Data Source
AI summary
Disclosed herein are compounds of formula I: and salts thereof. Also disclosed are compositions comprising compounds of formula I and methods using compounds of formula I.